New Delhi, Oct. 23 -- The Central Drugs Standard Control Organisation (CDSCO) has identified 330 drug samples as Not of Standard Quality (NSQ) and one spurious drug sample during its routine regulatory surveillance for September 2026.

According to the monthly report, Central Drugs Laboratories identified 42 drug samples as NSQ, while State Drugs Testing Laboratories identified 288 such samples.

The identification of drug samples as NSQ is based on their failure to meet one or more specified quality parameters.

CDSCO clarified that the failure is specific to the drug products belonging to the batch tested by the government laboratory and does not warrant concerns about other drug products available in the market.

Further, one drug samp...